Table 2 Univariate and multivariate Cox proportional hazards regression models for progression free survival
| Â | Univariate | Multivariate | ||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
D Group, B Group | 0.97 (0.64, 1.46) | 0.879 | 1.11 (0.72, 1.72) | 0.628 |
Age (≥ 65, < 65 years) | 0.97 (0.64, 1.46) | 0.874 | 1.04 (0.66, 1.66) | 0.862 |
Use of BMA, No use | 1.26 (0.84, 1.89) | 0.255 | 1.71 (1.06, 2.77) | 0.028 |
Chemotherapy, No use | 1.03 (0.55, 1.93) | 0.930 | 1.19 (0.60, 2.37) | 0.618 |
BMI ≥ 25, < 25 | 1.85 (1.16, 2.96) | 0.010 | 1.84 (1.11, 3.04) | 0.018 |
PgR+, − | 1.02 (0.60, 1.72) | 0.952 | 0.70 (0.38, 1.29) | 0.257 |
Visceral, No visceral | 1.98 (1.27, 3.08) | 0.002 | 2.13 (1.31, 3.49) | 0.003 |
Metastatic, De novo | 1.05 (0.65, 1.69) | 0.855 | 0.87 (0.49, 1.54) | 0.625 |
Endocrine therapy 2, 0–1 | 1.34 (0.80, 2.22) | 0.265 | 1.13 (0.60, 2.13) | 0.701 |
Endocrine therapy 3, 0–1 | 1.22 (0.76, 1.96) | 0.409 | 0.95 (0.56, 1.62) | 0.856 |
Incidence of oral mucositis within 8 weeks, None | 1.19 (0.69, 2.04) | 0.536 | 1.41 (0.78, 2.57) | 0.260 |